Sánchez-Pérez Sònia, Celorio-Sardà Ricard, Veciana-Nogués M Teresa, Latorre-Moratalla M Luz, Comas-Basté Oriol, Vidal-Carou M Carmen
Departament de Nutrició, Ciències de l'Alimentació i Gastronomia, Facultat de Farmàcia i Ciències de l'Alimentació, Campus de l'Alimentació de Torribera, Universitat de Barcelona, Santa Coloma de Gramenet, Spain.
Institut de Recerca en Nutrició i Seguretat Alimentària (INSA-UB), Universitat de Barcelona, Santa Coloma de Gramenet, Spain.
Front Nutr. 2022 Oct 12;9:973682. doi: 10.3389/fnut.2022.973682. eCollection 2022.
Efforts are currently being directed to identify a non-invasive marker that can serve as a solid and clinically irrefutable diagnostic criterion for histamine intolerance associated with diamine oxidase (DAO) deficiency. Accordingly, the identification of biomarkers of histamine (HA) metabolism in urine is proposed as a possible new diagnostic strategy. It is hypothesized that individuals with histamine intolerance could have a different urinary profile of HA and its metabolites in comparison with the healthy population. Thus, the aim of this study was to assess the urinary excretion of HA and 1-methylhistamine (MHA) in individuals diagnosed with histamine intolerance and in a control group. Levels of HA and MHA were compared between 24 h and first morning spot urine in a subgroup of 14 control individuals. Then, HA and MHA concentrations in spot urine of 32 histamine intolerant and 55 control individuals were determined by ultra-high performance liquid chromatography and fluorometric detection (UHPLC-FL) and normalized by creatinine. No differences were found between HA and MHA levels in 24 h and first morning samples. Overall, histamine intolerant patients presented a distinct urinary excretion profile compared to the control group due to lower levels of MHA. No differences in urinary MHA were observed related to serum DAO activity. Spot urine samples were thus validated as a reliable tool to determine the urinary excretion of HA and MHA. These results constitute a starting point for the study of HA metabolomics as a suitable and non-invasive approach to histamine intolerance diagnosis.
目前正在努力寻找一种非侵入性标志物，该标志物可作为与二胺氧化酶（DAO）缺乏相关的组胺不耐受的可靠且临床无可辩驳的诊断标准。因此，提出将尿液中组胺（HA）代谢生物标志物的鉴定作为一种可能的新诊断策略。据推测，与健康人群相比，组胺不耐受个体的尿液中HA及其代谢物的谱可能不同。因此，本研究的目的是评估被诊断为组胺不耐受的个体和对照组中HA和1-甲基组胺（MHA）的尿排泄情况。在14名对照个体的亚组中比较了24小时尿液和晨尿中HA和MHA的水平。然后，通过超高效液相色谱和荧光检测（UHPLC-FL）测定32名组胺不耐受个体和55名对照个体的晨尿中HA和MHA的浓度，并以肌酐进行标准化。24小时尿液和晨尿样本中HA和MHA水平未发现差异。总体而言，由于MHA水平较低，组胺不耐受患者与对照组相比呈现出明显不同的尿排泄谱。未观察到尿MHA与血清DAO活性相关的差异。因此，晨尿样本被确认为测定HA和MHA尿排泄的可靠工具。这些结果构成了研究HA代谢组学作为组胺不耐受诊断的合适且非侵入性方法的起点。
